20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
A better delivery of Dopamine
People with Parkinson’s have a severe reduction in levels of a protein called dopamine in their brains. Lower levels of dopamine are associated with the motor symptoms of the condition (slowness and rigidity of movement). Doctors prescribe treatments that replace this lost dopamine as a…
3P: Parkinson Postdoc Program Seminars
Cure Parkinson’s, Van Andel Institute and World Parkinson Coalition Institute present: The 3P Parkinson Postdoc Program Seminars
Time to re-nurture neurturin?
A new research report suggests that a disappointing gene therapy treatment did have an effect inside the brain, which could now have important implications for future gene therapy trials.
Exenatide: further studies initiated
In 2012, Cure Parkinson’s initiated the International Linked Clinical Trials (iLCT) programme to focus on identifying and prioritising potentially disease-modifying therapies for Parkinson’s. The first drug to be prioritised within the programme by the iLCT committee was a diabetes medication called exenatide. Since then, Cure Parkinson’s has…
Multi-Arm Multi-Stage trials for Parkinson’s
At present, most clinical trials for Parkinson’s involve a single therapy, being tested against a ‘placebo’ or control treatment for a fixed period of time. At the end of the study, the results are compiled and analysed, allowing for conclusions to be made. The whole…